Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA)
Publié dansClinical Rheumatology, vol. 36, no. 4, p. 773-779
Date de publication2017
Résumé
Mots-clés
- Abatacept/administration & dosage/adverse effects
- Adult
- Aged
- Antirheumatic Agents/administration & dosage/adverse effects
- Arthritis, Rheumatoid/drug therapy
- Body Mass Index
- Europe
- Female
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Multivariate Analysis
- Proportional Hazards Models
- Prospective Studies
- Registries
- Remission Induction
- Rheumatoid Factor/blood
- Treatment Outcome
Structure d'affiliation
Groupe de recherche
Citation (format ISO)
IANNONE, Florenzo et al. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the ‘pan-European registry collaboration for abatacept (PANABA). In: Clinical Rheumatology, 2017, vol. 36, n° 4, p. 773–779. doi: 10.1007/s10067-016-3505-5
Fichiers principaux (1)
Article (Published version)
Identifiants
- PID : unige:110908
- DOI : 10.1007/s10067-016-3505-5
- PMID : 27966068
ISSN du journal0770-3198